Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immunogenicity Non-inferiority Immuno-bridging Study of a Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58) Vaccine (E.Coli) in Healthy Population Aged 9-17 Years Old vs Aged 18-26 Years Old

NCT05056402 is registered in ClinicalTrials.gov with Xiamen University as lead sponsor.

NCT NCT05056402
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05056402 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immunogenicity Non-inferiority Immuno-bridging Study of a Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58) Vaccine (E.Coli) in Healthy Population Aged 9-17 Years Old vs Aged 18-26 Years Old
Lead sponsor
Xiamen University
Phase
Phase 3
Overall status
Active, not recruiting
Start date
September 19, 2021
Completion date
December 31, 2025
Enrollment
1,382 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cervical cancer, condylomata acuminata